Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

医学 安慰剂 便秘 肠易激综合征 临床终点 内科学 不利影响 腹痛 胃肠病学 排便 随机对照试验 病理 替代医学
作者
William D. Chey,Anthony Lembo,Bernard J. Lavins,Steven J. Shiff,Allen W. Mangel,Mark G. Currie,James E. MacDougall,Xinwei D. Jia,James Shao,Donald A. Fitch,Mollie Baird,Harvey Schneier,Jeffrey M. Johnston
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:107 (11): 1702-1712 被引量:408
标识
DOI:10.1038/ajg.2012.254
摘要

OBJECTIVES: Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide treatment in patients with irritable bowel syndrome with constipation (IBS-C) over 26 weeks. METHODS: This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients to placebo or 290 μg of oral linaclotide once daily for a 26-week treatment period. The primary and the secondary efficacy assessments were evaluated over the first 12 weeks of treatment. Primary end points included the Food and Drug Administration's (FDA's) end point for IBS-C (responder: a patient who reported (i) improvement of ≥30% from baseline in average daily worst abdominal pain score and (ii) increase of ≥1 complete spontaneous bowel movement (CSBM) from baseline, both in the same week for ≥6/12 weeks) and three other primary end points, based on improvements in abdominal pain and CSBMs for 9/12 weeks. Adverse events (AEs) were monitored. RESULTS: In all, 804 patients (mean age=44 years, female=90%, white=78%) were evaluated; 33.7% of linaclotide-treated patients were FDA end point responders, vs. 13.9% of placebo-treated patients (P<0.0001) (number needed to treat=5.1, 95% confidence interval (CI): 3.9, 7.1). The pain responder criterion of the FDA end point was met by 48.9% of linaclotide-treated patients vs. 34.5% of placebo-treated patients (number needed to treat=7.0, 95% CI: 4.7, 13.1), and the CSBM responder criterion was met by 47.6% of linaclotide-treated patients, vs. 22.6% of placebo patients (number needed to treat=4.0, 95% CI: 3.2, 5.4). Remaining primary end points (P<0.0001) and all secondary end points (P<0.001), including abdominal pain, abdominal bloating, and bowel symptoms (SBM and CSBM rates, Bristol Stool Form Scale (BSFS) score, and straining), were also statistically significantly improved with linaclotide vs. placebo. Statistically significant differences from placebo were observed for responder and continuous end points over 26 weeks of treatment. AE incidence was similar between treatment groups, except for diarrhea, which caused discontinuation in 4.5% of linaclotide patients vs. 0.2% of placebo patients. CONCLUSIONS: Linaclotide 290 μg once daily significantly improved abdominal and bowel symptoms associated with IBS-C over 26 weeks of treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI5应助cc采纳,获得10
刚刚
铜泰妍完成签到 ,获得积分10
1秒前
贝贝完成签到 ,获得积分10
6秒前
Lrcx完成签到 ,获得积分10
7秒前
Wen完成签到 ,获得积分10
8秒前
盘尼西林完成签到 ,获得积分10
10秒前
LOVE0077完成签到,获得积分10
13秒前
zhao完成签到,获得积分10
15秒前
BINBIN完成签到 ,获得积分10
25秒前
ambrose37完成签到 ,获得积分10
27秒前
量子星尘发布了新的文献求助10
33秒前
fufufu123完成签到 ,获得积分10
37秒前
开心的大娘完成签到,获得积分10
37秒前
www完成签到 ,获得积分10
39秒前
末末完成签到 ,获得积分10
49秒前
无为完成签到 ,获得积分10
50秒前
白嫖论文完成签到 ,获得积分10
52秒前
上官若男应助忧伤的步美采纳,获得10
55秒前
科研通AI2S应助科研通管家采纳,获得10
55秒前
58秒前
从心随缘完成签到 ,获得积分10
59秒前
花花发布了新的文献求助10
1分钟前
牛奶面包完成签到 ,获得积分10
1分钟前
1分钟前
岁月如歌完成签到 ,获得积分0
1分钟前
1分钟前
Li完成签到,获得积分10
1分钟前
张琨完成签到 ,获得积分10
1分钟前
1分钟前
sunnyqqz完成签到,获得积分10
1分钟前
热情的乘风完成签到,获得积分20
1分钟前
1分钟前
霍凡白完成签到,获得积分10
1分钟前
1分钟前
Feng发布了新的文献求助20
1分钟前
怕孤单的若颜完成签到 ,获得积分10
1分钟前
1分钟前
ruochenzu发布了新的文献求助10
1分钟前
zhongu发布了新的文献求助10
1分钟前
阳光彩虹小白马完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022